Mike Solomon
January 6, 2021 06:30 AM ESTUpdated January 8, 10:15 AM
Deals

Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

John Carroll

Editor & Founder

Roche has a big ap­petite for all things in­volv­ing drug­ging RNA. And they just or­dered a fresh help­ing to see if they can start to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times